169 related articles for article (PubMed ID: 36945513)
1. Structural basis for differential p19 targeting by IL-23 biologics.
Daniele SG; Eldirany SA; Ho M; Bunick CG
bioRxiv; 2023 Mar; ():. PubMed ID: 36945513
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis for p19 Targeting by Anti-IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis.
Daniele SG; Eldirany SA; Damiani G; Ho M; Bunick CG
JID Innov; 2024 Mar; 4(2):100261. PubMed ID: 38445231
[TBL] [Abstract][Full Text] [Related]
3. A non-clinical comparative study of IL-23 antibodies in psoriasis.
Zhou L; Wang Y; Wan Q; Wu F; Barbon J; Dunstan R; Gauld S; Konrad M; Leys L; McCarthy R; Namovic M; Nelson C; Overmeyer G; Perron D; Su Z; Wang L; Westmoreland S; Zhang J; Zhu R; Veldman G
MAbs; 2021; 13(1):1964420. PubMed ID: 34460338
[TBL] [Abstract][Full Text] [Related]
4. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
[TBL] [Abstract][Full Text] [Related]
5. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL 23 biologics for the treatment of plaque psoriasis.
Vu A; Ulschmid C; Gordon KB
Expert Opin Biol Ther; 2022 Dec; 22(12):1489-1502. PubMed ID: 36243011
[TBL] [Abstract][Full Text] [Related]
7. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis.
Fragoulis GE; Siebert S
Musculoskeletal Care; 2022 Nov; 20 Suppl 1(Suppl 1):S12-S21. PubMed ID: 36069174
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
9. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
Gottlieb AB; Saure D; Wilhelm S; Dossenbach M; Schuster C; Smith SD; Ramot Y; Thaçi D
J Dermatolog Treat; 2022 Feb; 33(1):54-61. PubMed ID: 32299269
[TBL] [Abstract][Full Text] [Related]
12. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
[TBL] [Abstract][Full Text] [Related]
13. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
[TBL] [Abstract][Full Text] [Related]
14. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
Blauvelt A; Chiricozzi A; Ehst BD; Lebwohl MG
Adv Ther; 2023 Aug; 40(8):3410-3433. PubMed ID: 37330926
[TBL] [Abstract][Full Text] [Related]
15. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB
PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060
[TBL] [Abstract][Full Text] [Related]
16. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
Boehncke WH; Brembilla NC; Nissen MJ
Expert Rev Clin Immunol; 2021 Jan; 17(1):5-13. PubMed ID: 33251833
[TBL] [Abstract][Full Text] [Related]
17. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
[TBL] [Abstract][Full Text] [Related]
18. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
19. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
20. Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab.
Campbell K; Li K; Yang F; Branigan P; Elloso MM; Benson J; Orlovsky Y; Chen Y; Garcet S; Krueger JG
Immunohorizons; 2023 Apr; 7(4):273-285. PubMed ID: 37071038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
